Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lab Directors Look For Ways To Adjust To Proposed LDT Framework

This article was originally published in The Gray Sheet

Executive Summary

While many in the laboratory community protested loudly against FDA's plans to regulate lab-developed tests at a recent workshop, some tried to look ahead to how they could smoothly adjust to a dual regulatory system in which labs are regulated by CMS, while tests are approved by FDA.


Related Content

US Spending Bill Rider Looks To Stop Already Halted FDA LDT Guidance
Clinical Labs Lawyer Up In Battle Over LDTs
FDA Releases LDT Regulatory Framework, Notification Draft Guidances


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts